Engineering the best transplant outcome for high-risk acute myeloid leukemia: the donor, the graft and beyond.

T cell depletion acute myeloid leukemia novel cellular therapies

Journal

Cytotherapy
ISSN: 1477-2566
Titre abrégé: Cytotherapy
Pays: England
ID NLM: 100895309

Informations de publication

Date de publication:
04 Dec 2023
Historique:
received: 16 11 2023
accepted: 16 11 2023
medline: 6 12 2023
pubmed: 6 12 2023
entrez: 6 12 2023
Statut: aheadofprint

Résumé

Allogeneic hemopoietic cell transplantation remains the goal of therapy for high-risk acute myeloid leukemia (AML). However, treatment failure in the form of leukemia relapse or severe graft-versus-host disease remains a critical area of unmet need. Recently, significant progress has been made in the cell therapy-based interventions both before and after transplant. In this review, the Stem Cell Engineering Committee of the International Society for Cell and Gene Therapy summarizes the literature regarding the identification of high risk in AML, treatment approaches before transplant, optimal transplant platforms and measures that may be taken after transplant to ideally prevent, or, if need be, treat AML relapse. Although some strategies remain in the early phases of clinical investigation, they are built on progress in pre-clinical research and cellular engineering techniques that are already improving outcomes for children and adults with high-risk malignancies.

Identifiants

DOI: 10.1016/j.jcyt.2023.11.004 PMID: 38054912
pubmed: 38054912
pii: S1465-3249(23)01103-9
doi: 10.1016/j.jcyt.2023.11.004
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2023 International Society for Cell & Gene Therapy. All rights reserved.

Auteurs

Safia Belbachir (S)

Haematology Department, Fiona Stanley Hospital, Perth, Western Australia, Australia.

Allistair Abraham (A)

Center for Cancer and Immunology Research, CETI, Children's National Hospital, Washington, District of Columbia, USA.

Akshay Sharma (A)

Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.

Susan Prockop (S)

Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts USA.

Amy E DeZern (AE)

Bone Marrow Failure and MDS Program, John Hopkins Medicine, Baltimore, Maryland, USA.

Carmem Bonfim (C)

Pediatric Blood and Marrow Transplantation Division/Instituto de Pesquisa Pele Pequeno Principe Research/Faculdades Pequeno Príncipe, Curitiba, Brazil.

Alan Bidgoli (A)

Division of Blood and Marrow Transplantation, Children's Healthcare of Atlanta, Aflac Blood and Cancer Disorders Center, Emory University, Atlanta, Georgia, USA.

Jinjing Li (J)

Graduate School of Biomedical Engineering, University of New South Wales, Sydney, New South Wales, Australia.

Annalisa Ruggeri (A)

IRCCS Ospedale San Raffaele, Segrate, Milan, Italy.

Alice Bertaina (A)

Division of Hematology, Oncology, Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, Stanford University, Stanford, California, USA.

Jaap Jan Boelens (JJ)

Stem Cell Transplantation and Cellular Therapies, Memorial Sloan Kettering Cancer Center, and Department of Pediatrics, Weill Cornell Medical College of Cornell University, New York, New York, USA.

Duncan Purtill (D)

Haematology Department, Fiona Stanley Hospital, Perth, Western Australia, Australia; PathWest Laboratory Medicine, Perth, Western Australia, Australia. Electronic address: duncan.purtill@health.wa.gov.au.

Classifications MeSH